TBVI symposium: Update on TB vaccine development

Tuesday 29 January 15.00 – 19.00h, Les Diablerets, Switzerland

This symposium is open to everyone: NEWTBVAC partners, TB-TEA partners and other invited participants

15.00-16.20 Early TB vaccine development
Chair: Juhani Eskola (Chair TBVI Steering Committee)

- TB Vaccines that Induce Bactericidal Immunity – Michelle Larsen, Albert Einstein College of Medicine
- The vaccine development portfolio at Aeras – Barry Walker, Aeras
- Translational animal models for TB vaccines – Ann Williams, Health Protection Agency
- Antigen discovery programme – David Lewinsohn, Oregon Health & Science University (title to be confirmed)

16.20-16.50 Break

16.50-18.50 TB vaccines in clinical development
Chair: Luc Hessel (Chair Clinical development team TBVI)

- MVA85A, update on recent trials – Helen McShane, Oxford University
- M72 vaccine development program – Gérald Voss, or Stéphane Temmerman, GSK
- H1/H56 – Peter Andersen, SSI
- AdHu5Ag85A TB vaccine: current clinical development and future prospects – Zhou Xing, McMaster University
- VPM1002 TB Vaccine: A BCG replacement on the horizon - Leander Grode, VPM
- Steps toward the development of MTBVAC - Carlos Martin, University of Zaragoza

19.30 Dinner

For more information, please contact erna.balk@tbvi.eu